Second-line drug resistance in multidrug-resistant tuberculosis cases of various origins in the Netherlands

International Journal of Tuberculosis and Lung Disease

Volumn 12, Issue 11, 2008, Pages 1295-1299

  Van Ingen, Jakko ^a,b   Boeree, M J ^a   Wright, A ^c   Van Der Laan, T ^b   Dekhuijzen, P N R ^a   Van Soolingen, D ^b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^c WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

Extensively drug resistant tuberculosis; Multidrug resistant; Tuberculosis

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMINOSALICYLIC ACID; CIPROFLOXACIN; CLOFAZIMINE; CYCLOSERINE; ETHAMBUTOL; ISONIAZID; KANAMYCIN; LINEZOLID; PROTIONAMIDE; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFABUTIN; RIFAMPICIN; STREPTOMYCIN; THIOACETAZONE;

ADOLESCENT; ADULT; AFRICAN AMERICAN; AGED; ARTICLE; ASIA; BACTERIUM ISOLATION; CONTROLLED STUDY; DATA BASE; DRUG SENSITIVITY; EUROPE; FEMALE; GEOGRAPHIC ORIGIN; HUMAN; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; NETHERLANDS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; SOUTHEAST ASIA; TREATMENT DURATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; EMIGRANTS AND IMMIGRANTS; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; NETHERLANDS; RESIDENCE CHARACTERISTICS; RETROSPECTIVE STUDIES;

EID: 56249148550     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Gandhi N R, Moll A, Sturm A W, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006; 368: 1575-1580.
2. Frieden T R, Sterling T, Pablos-Mendez A, Kilburn J O, Cauthen G M, Dooley S W. The emergence of drug-resistant tuberculosis in New York City. N Engl J Med 1993; 328: 521-526.
3. Lambregts-van Weezenbeek C S, Jansen H M, Nagelkerke N J, van Klingeren B, Veen J. Nationwide surveillance of drug-resistant tuberculosis in The Netherlands: rates, risk factors and treatment outcome. Int J Tuberc Lung Dis 1998; 2: 288-295.
4. van Klingeren B, Dessens-Kroon M, van der Laan T, Kremer K, van Soolingen D. Drug susceptibility testing of Mycobacterium tuberculosis complex using a high throughput, reproducible, absolute concentration method. J Clin Microbiol 2007; 45: 2662-2668.
5. Samper S, Martin C, Pinedo A, et al. Transmission between HIV-infected patients of multidrug-resistant tuberculosis caused by Mycobacterium bovis. AIDS 1997; 11: 1237-1242.
6. Shah N S, Wright A, Bai G H, et al. Worldwide emergence of extensively drug-resistant tuberculosis. Emerg Infect Dis 2007; 13: 380-387.
7. Nathanson E, Gupta R, Huamani P, et al. Adverse events in the treatment of multidrug-resistant tuberculosis: results from the DOTS-Plus initiative. Int J Tuberc Lung Dis 2004; 8: 1382-1384.
8. Spigelman M K. New tuberculosis therapeutics: a growing pipeline. J Infect Dis 2007; 196 (Suppl 1): S28-S34.
9. Ordway D, Viveiros M, Leandro C, et al. Clinical concentrations of thioridazine kill intracellular multidrug-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 2003; 47: 917-922.
10. Rustomjee R, Lienhardt C, Kanyok T, et al., Gatifloxacin for TB (OFLOTUB) study team. A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 2008; 12: 128-138.
11. Ginsburg A S, Grosset J H, Bishai W R. Fluoroquinolones, tuberculosis and resistance. Lancet Infect Dis 2003; 3: 432-442.
12. Toungoussova O S, Mariandyshev A O, Bjune G, Caugant D A, Sandven P. Resistance of multidrug-resistant strains of Mycobacterium tuberculosis from the Archangel oblast, Russia, to second-line anti-tuberculosis drugs. Eur J Clin Microbiol Infect Dis 2005; 24: 202-206.
13. Prammananan T, Arjratanakool W, Chaiprasert A, et al. Second-line drug susceptibilities of Thai multidrug-resistant Mycobacterium tuberculosis isolates. Int J Tuberc Lung Dis 2005; 9: 216-219.
14. Umubyeyi A, Rigouts L, Shamputa I C, Dediste A, Struelens M, Portaels F. Low levels of second-line drug resistance among multidrug-resistant Mycobacterium tuberculosis isolates from Rwanda. Int J Infect Dis 2008; 12: 152-156.
15. Morlock G P, Metchock B, Sikes D, Crawford J T, Cooksey R C. ethA, inhA, and katG loci of ethionamide-resistant clinical Mycobacterium tuberculosis isolates. Antimicrob Agents Chemother 2003; 47: 3799-3805.
16. Afanas'ev M V, Ikryannikova L N, Il'ina E N, et al. Molecular characteristics of rifampicin- and isoniazid-resistant Mycobacterium tuberculosis isolates from the Russian Federation. J Antimicrob Chemother 2007; 59: 1057-1064.
17. Sajduda A, Brzostek A, Poplawska M, et al. Molecular characterization of rifampin- and isoniazid-resistant Mycobacterium tuberculosis strains isolated in Poland. J Clin Microbiol 2004; 42: 2425-2431.
18. Cavusoglu C, Karaca-Derici Y, Bilgic A. In vitro activity of rifabutin against rifampicin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations. Clin Microbiol Infect 2004; 10: 662-665.
19. Bakonyte D, Baranauskaite A, Cicenaite J, Sosnovskaja A, Stakenas P. Mutations in the rpoB gene of rifampicin resistant Mycobacterium tuberculosis clinical isolates from Lithuania. Int J Tuberc Lung Dis 2005; 9: 936-938.